1 Zhou X,Pan H,Yang P,et al.Both chronic HBV infection and naturally acquired HBV immunity confer increased risks of B-cell non-Hodgkin lymphoma[J].BMC Cancer,2019,19(1):477. 2 Ansell SM.Non-hodgkin lymphoma:diagnosis and treatment[J].Mayo Clin Proc,2015,90(8):1152-1163. 3 Miranda-Filho A,Piñeros M,Znaor A,et al.Global patterns and trends in the incidence of non-hodgkin lymphoma[J].Cancer Causes Control,2019,30(5):489-499. 4 Yamaguchi M,Suzuki R,Oguchi M.Advances in the treatment of extranodal NK/T-cell lymphoma,nasal type[J].Blood,2018,131(23):2528-2540. 5 Brown JM,Recht L,Strober S.The promise of targeting macrophages in cancer therapy[J].Clin Cancer Res,2017,23(13):3241-3250. 6 Mantovani A,Marchesi F,Malesci A,et al.Tumour-associated macrophages as treatment targets in oncology[J].Nat Rev Clin Oncol,2017,14(7):399-416. 7 欧阳明祈.PD-1表达水平对非霍金淋巴瘤中肿瘤相关巨噬细胞功能影响的研究[D].北京:北京协和医学院,2018. 8 Wu C,Wu X,Liu X,et al.Prognostic significance of monocytes and monocytic myeloid-derived suppressor cells in diffuse large B-cell lymphoma treated with r-chop[J].Cell Physiol Biochem,2016,39(2):521-530. 9 George A,Prince HM,Szer J,et al.Prognostic impact of monocyte count at presentation in mantle cell lymphoma[J].Br J Haematol,2014,164(6):890-893. 10 Wang H,Li P,Wang L,et al.High numbers of CD68+ tumor-associated macrophages correlate with poor prognosis in extranodal NK/T-cell lymphoma,nasal type[J].Ann Hematol,2015,94(9):1535-1544. 11 Kato A,Imai Y,Aoki K,et al.Serum IgA level,monocyte count,and international prognostic index are independently associated with overall survival in patients with HTLV-I-negative nodal peripheral T cell lymphoma[J].Ann Hematol,2014,93(7):1185-1191. 12 Yang YQ,Liang JH,Wu JZ,et al.Elevated absolute monocyte count predicts unfavorable outcomes in patients with angioimmunoblastic T-cell lymphoma[J].Leuk Res,2016,42:88-92. 13 Lee SF,Luque-Fernandez MA.Prognostic value of lymphocyte-to-monocyte ratio and neutrophil-to-lymphocyte ratio in follicular lymphoma:a retrospective cohort study[J].BMJ Open,2017,7(11):e017904. 14 Li N,Zhang L,Song HL,et al.Prognostic impact of absolute lymphocyte count/absolute monocyte count ratio and prognostic score in patients with nasal-type,extranodal natural killer/T-cell lymphoma[J].Tumour Biol,2017,(39)5:1-11. 15 Li Q,Gao S,Ma J,et al.A lower ALC/AMC ratio is associated with poor prognosis of peripheral T cell lymphoma-not otherwise specified[J].Leuk Res,2018,73:5-11. 16 Jia T,Zhang R,Zhu HY,et al.Prognostic significance of peripheral blood absolute monocyte count and lymphocyte to monocyte ratio in anaplastic large cell lymphoma[J].Cancer Biomark,2018,22(4):807-813. 17 Matsuki E,Bohn OL,EI Jamal S,et al.Lymphocyte-to-monocyte ratio may serve as a better prognostic indicator than tumor-associated macrophages in DLBCL treated with rituximab[J].Appl Immunohistochem Mol Morphol,2019,27(8):572-580. 18 Sugimoto T,Watanabe T.Follicular lymphoma:the role of the tumor microenvironment in prognosis[J].J Clin Exp Hematop,2016,56(1):1-19. 19 Lin ZX,Bai B,Cai QC,et al.High numbers of tumor-associated macrophages correlate with poor prognosis in patients with mature T-and natural killer cell lymphomas[J].Med Oncol,2012,29(5):3522-3528. 20 Liu Y,Fan L,Wang Y,et al.Tumor-associated macrophages promote tumor cell proliferation in nasopharyngeal NK/T-cell lymphoma[J].Int J Clin Exp Pathol,2014,7(9):5429-5435. 21 Ham JS,Park HY,Ryu KJ,et al.Elevated serum interleukin-10 level and M2 macrophage infiltration are associated with poor survival in angioimmunoblastic T-cell lymphoma[J].Oncotarget,2017,8(44):76231-76240. 22 Niino D,Komohara Y,Murayama T,et al.Ratio of M2 macrophage expression is closely associated with poor prognosis for angioimmunoblastic T-cell lymphoma(AITL)[J].PatholInt,2010,60(4):278-283. 23 Pedersen MB,Danielsen AV,Hamilton-Dutoit SJ,et al.High intratumoral macrophage content is an adverse prognostic feature in anaplastic large cell lymphoma[J].Histopathology,2014,65(4):490-500. 24 Komohara Y,Niino D,Saito Y,et al.Clinical significance of CD163+ tumor-associated macrophages in patients with adult T-cell leukemia/lymphoma[J].Cancer Sci,2013,104(7):945-951. 25 Sugaya M,Miyagaki T,Ohmatsu H,et al.Association of the numbers of CD163+ cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma[J].J Dermatol Sci,2012,68(1):45-51. 26 Zhang W,Wang L,Zhou D,et al.Expression of tumor-associated macrophages and vascular endothelial growth factor correlates with poor prognosis of peripheral T-cell lymphoma,not otherwise specified[J].Leuk Lymphoma,2011,52(1):46-52. 27 Noyori O,Komohara Y,Nasser H,et al.Expression of IL-34 correlates with macrophage infiltration and prognosis of diffuse large B-cell lymphoma[J].Clin Transl Immunology,2019,8(8):e1074. 28 Ishii H,Takahara M,Nagato T,et al.Monocytes enhance cell proliferation and LMP1 expression of nasal natural killer/T-cell lymphoma cells by cell contact dependent interaction through membrane-bound IL-15[J].Int J Cancer,2012,130(1):48-58. 29 Xiu B,Lin Y,Grote DM,et al.IL-10 induces the development of immunosuppressive CD14(+)HLA-DR(low/-)monocytes in B-cell non-Hodgkin lymphoma[J].Blood Cancer J,2015,31:e328. 30 Voss JJLP,Ford CA,Petrova S,et al.Modulation of macrophage antitumor potential by apoptotic lymphoma cells[J].Cell Death Differ,2017,24(6):971-983. 31 Mendoza-Coronel E,Ortega E.Macrophage polarization modulates FcgR-and CD13-mediated phagocytosis and reactive oxygen species production,independently of receptor membrane expression[J].Front Immunol,2017,8:303. 32 Chaudhari P,Ye Z,Jang YY.Roles of reactive oxygen species in the fate of stem cells[J].Antioxid Redox Signal,2014,20(12):1881-1890. 33 Lin YM,Huang YL,Fong YC,et al.Hepatocyte growth factor increases vascular endothelial growth factor-A production in human synovial fibroblasts through c-met receptor pathway[J].PLoS One,2012,7(11):e50924. 34 Huang W,Wei X,Wei Y,et al.Biology of tumor associated macrophages in diffuse large B cell lymphoma[J].DNA Cell Biol,2018[Online ahead of print]. 35 Vari F,Arpon D,Keane C,et al.Immune evasion via PD-1/PD-L1 on NK-Cells and monocyte/macrophages is more prominent in hodgkin lymphoma than DLBCL[J].Blood,2018,131(16):1809-1819. 36 McKee SJ,Tuong ZK,Kobayashi T,et al.B cell lymphoma progression promotes the accumulation of circulating Ly6Clo monocytes with immunosuppressive activity[J].Oncoimmunology,2017,7(2):e1393599. 37 Church AK,VanDerMeid KR,Baig NA,et al.Anti-CD20 monoclonal antibody-dependent phagocytosis of chronic lymphocytic leukaemia cells by autologous macrophages[J].Clin Exp Immunol,2016,183(1):90-101. 38 Sawas A,Farber CM,Schreeder MT,et al.A phase 1/2 trial of ublituximab,a novel anti-CD20 monoclonal antibody,in patients with B-cell non-hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab[J].Br J Haematol,2017,177(2):243-253. 39 Chao MP,Alizadeh AA,Tang C,et al.Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-hodgkin lymphoma[J].Cell,2010,142(5):699-713. 40 Advani R,Flinn I,Popplewell L,et al.CD47 blockade by Hu5F9-G4 and rituximab in non-hodgkin's lymphoma[J].N Engl J Med,2018,379(18):1711-1721. 41 He J,Hu Y,Hu M,et al.Development of PD-1/PD-L1 pathway in tumor immune microenvironment and treatment for non-small cell lung cancer[J].Sci Rep,2015,5:13110. 42 Kwong YL,Chan TSY,Tan D,et al.PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase[J].Blood,2017,129(17):2437-2442. 43 Lesokhin AM,Ansell SM,Armand P,et al.Nivolumab in patients with relapsed or refractory hematologic malignancy:preliminary results of a phase ib study[J].J Clin Oncol,2016,34(23):2698-2704. 44 Priceman SJ,Sung JL,Shaposhnik Z,et al.Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1receptor:combating tumor evasion of antiangiogenic therapy[J].Blood,2010,115(7):1461-1471. |